Phil Nadeau

Stock Analyst at TD Cowen

(2.71)
# 1,929
Out of 5,049 analysts
23
Total ratings
42.86%
Success rate
34.49%
Average return

Stocks Rated by Phil Nadeau

Apellis Pharmaceuticals
Oct 31, 2025
Maintains: Buy
Price Target: $50$45
Current: $19.71
Upside: +128.31%
Kura Oncology
Nov 21, 2024
Reiterates: Buy
Price Target: n/a
Current: $10.16
Upside: -
Rhythm Pharmaceuticals
Nov 6, 2024
Maintains: Buy
Price Target: $55$65
Current: $98.49
Upside: -34.00%
Biogen
Oct 31, 2024
Maintains: Buy
Price Target: $300$275
Current: $156.74
Upside: +75.45%
BioMarin Pharmaceutical
Aug 6, 2024
Maintains: Buy
Price Target: $125$120
Current: $51.84
Upside: +131.48%
Vertex Pharmaceuticals
Jul 23, 2024
Maintains: Buy
Price Target: $450$500
Current: $416.25
Upside: +20.12%
Enliven Therapeutics
Mar 3, 2023
Initiates: Outperform
Price Target: n/a
Current: $18.30
Upside: -
MoonLake Immunotherapeutics
Jul 7, 2022
Initiates: Outperform
Price Target: n/a
Current: $10.29
Upside: -
Aura Biosciences
Nov 23, 2021
Initiates: Outperform
Price Target: n/a
Current: $5.41
Upside: -
Annexon
Aug 18, 2020
Initiates: Outperform
Price Target: n/a
Current: $3.02
Upside: -
Initiates: Outperform
Price Target: n/a
Current: $6.05
Upside: -